Istvan Takacs, Emese Mezosi, Alfonso Soto, Peter Kamenický, Lucile Figueres, Maria Angeles Galvez Moreno, Sandrine Lemoine, Francoise Borson-Chazot, Ismael Capel, Taha Ouldrouis, Nadège Lucas, Soraya Allas, Mark Sumeray, Michel Ovize, Michael Mannstadt
CONTEXT: Hypoparathyroidism is a rare disorder characterized by a deficiency in parathyroid hormone (PTH) resulting in hypocalcemia, hyperphosphatemia, and hypercalciuria. Eneboparatide is an investigational peptide agonist of the PTH1 receptor for the treatment of chronic hypoparathyroidism (HP). OBJECTIVE: To evaluate the efficacy, safety, and tolerability of eneboparatide in HP patients. DESIGN: Open-label, phase 2 study. PARTICIPANTS: Twenty-eight patients (21 women, 7 men), mean age (range): 58 years (28-72), with HP were enrolled into 2 consecutive cohorts (C1, n = 12, and C2, n = 16)...
March 6, 2024: Journal of Clinical Endocrinology and Metabolism